BIRMINGHAM, Ala., Feb. 28 /PRNewswire-FirstCall/ -- BioCryst Pharmaceuticals (Nasdaq: BCRX) today announced that its fourth quarter and fiscal year 2007 financial results will be released on Tuesday, March 4, 2008. At 8:30 a.m. Eastern Time BioCryst will host a conference call and webcast to discuss the financial results and provide an update on the Company's programs and further clinical data. The call will be led by Jon P. Stonehouse, BioCryst's Chief Executive Officer, and Stuart Grant, BioCryst's Chief Financial Officer.
The webcast can be accessed by logging onto http://www.biocryst.com. Please connect to the website at least 15 minutes prior to the conference call to ensure adequate time for any software download that may be needed to hear the webcast. To participate in the conference call, please dial 1-800-860-2442 (U.S.) or 1-412-858-4600 (international). The audio portion of the webcast will be archived and available for replay for 14 days.
BioCryst Pharmaceuticals, Inc. is a leader in the use of
crystallography and structure-based drug design for the development of
novel therapeutics to treat cancer, cardiovascular diseases, autoimmune
diseases, and viral infections. The Company is advancing multiple internal
programs toward potential commercialization including forodesine HCl in
oncology, BCX-4208 in transplantation and autoimmune diseases and peramivir
in seasonal and life- threatening influenza. BioCryst has a worldwide
partnership with Roche for the development and commercialization of
BCX-4208, and is collaborating with Mundipharma for the development and
commercialization of forodesine HCl in markets across Europe, Asia,
|SOURCE BioCryst Pharmaceuticals|
Copyright©2008 PR Newswire.
All rights reserved